PhaseRx appoints Gordon Brandt chief medical officer
Dr. Brandt previously served as PhaseRx's chief clinical advisor, and has been working with the company for five years.
Prior to this, he served as president and executive vice president of clinical research and medical affairs for Nastech Pharmaceutical Company Inc. (which became MDRNA Inc.), where he worked to develop nucleic acid therapeutics.
Previously, Dr. Brandt worked at Sonus Pharmaceuticals, Inc., a developer of oncology drugs, where he held the positions of vice president, clinical and regulatory affairs, and director of medical affairs.
Dr. Brandt graduated from Yale University with a B.S. degree in engineering science, received an M.D. from the University of California, San Francisco, and completed his residency training in internal medicine at Kaiser Hospital in San Francisco.
He has worked in the medical device, biologic, and drug fields for more than 30 years, and has successfully led both US and EU drug approval programs. ■
LATEST MOVES FROM Washington
- Juno Therapeutics appoints Rupert Vessey to board
- HomeStreet appoints Mark R. Ruh as interim CFO
- Avalara appoints Tony Susak as general manager
- Red Lion Hotels adds two to board
- Expedia appoints Chelsea Clinton to board
More inside POST